Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19
06 janv. 2022 16h24 HE
|
Revive Therapeutics Ltd.
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 ...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
29 déc. 2021 16h45 HE
|
Revive Therapeutics Ltd.
Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and...
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
03 déc. 2021 09h31 HE
|
Revive Therapeutics Ltd.
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
03 déc. 2021 08h30 HE
|
Revive Therapeutics Ltd.
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
23 nov. 2021 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant
16 nov. 2021 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch
03 nov. 2021 07h00 HE
|
Revive Therapeutics Ltd.
Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) --...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
26 oct. 2021 08h15 HE
|
Revive Therapeutics Ltd.
DSMB support in continuing the Phase 3 clinical trial; No serious adverse events and safety concerns reported to date.Phase 3 clinical trial to incorporate viral load testing for a minimum of 300...
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
21 sept. 2021 09h45 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
17 août 2021 17h46 HE
|
Revive Therapeutics Ltd.
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research HospitalMedicinal mushroom compound with anticancer activities that have minimal effects on...